Skip to main content

Advertisement

SpringerLink
Log in

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of chemotherapy, but it may be prevented or mitigated with medications. Uncontrolled CINV can lead to reduced quality of life and can result in increased costs (due to health care utilization and missed work). We prospectively assessed the prevalence and burden of CINV in a US population.

Methods

Final analysis was performed on 178 patients, beginning chemotherapy during 2007–2008 at oncology specialty settings. Patients kept a diary recording use of antiemetic medications just before the start of chemotherapy and use of antiemetic medications, health care resources, and episodes of nausea and vomiting during the 5 days following. In addition, they completed a Functional Living Index—Emesis (FLIE) questionnaire and a Work Productivity and Assessment Inventory–Nausea and Vomiting assessment, to determine the impact of CINV on daily functioning and on work productivity, respectively. Physicians independently recorded prescribed medications and health care utilization.

Results

Of the patients, 61.2% reported experiencing CINV (34.3% with acute CINV and 58.4% with delayed CINV). Based on the FLIE assessment, 37.2% of all patients reported reduced daily functioning, and of those with poorly managed CINV, about 90% reported a significant impact on daily functioning. Total costs due to CINV were on average $778.58 per patient from the day of administration through the 5 days following the first cycle of chemotherapy; patients with more severe CINV typically had higher costs.

Conclusions

CINV remains a significant problem among US patients, suggesting a need for more effective prophylaxis use in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ballatori E, Roila F, Ruggeri B, Porrozzi S et al (2007) The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 15:31–38

    Article  PubMed  Google Scholar 

  2. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

    Article  PubMed  CAS  Google Scholar 

  3. Cohen L, de Moor CA, Eisenberg P, Ming EE et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503

    Article  PubMed  Google Scholar 

  4. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  PubMed  CAS  Google Scholar 

  5. Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? Support Oncol 2(Suppl 1):1–10

    Google Scholar 

  6. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494

    Article  PubMed  CAS  Google Scholar 

  7. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526–536

    Article  PubMed  CAS  Google Scholar 

  8. Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150

    Article  PubMed  CAS  Google Scholar 

  9. Lachaine J, Yelle L, Kaizer L, Dufour A et al (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2:181–187

    Article  PubMed  Google Scholar 

  10. Naeim A, Dy SM, Lorenz KA, Sanati H et al (2008) Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 26:3903–3910

    Article  PubMed  Google Scholar 

  11. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117–1122

    Article  PubMed  CAS  Google Scholar 

  12. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353–365

    Article  PubMed  CAS  Google Scholar 

  13. Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678–685

    Article  PubMed  Google Scholar 

  14. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ et al (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278–1285

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Jesse Potash and Lee Brekke at i3 Innovus for assistance with the preparation of this manuscript. Financial support for this study was provided by Glaxo Smith Kline.

Author information

Authors and Affiliations

  1. Global Health Outcomes-Oncology, GlaxoSmithKline, 1250 South Collegeville Road, Mail Code UP4110, Collegeville, PA, 19426, USA

    Amin Haiderali

  2. CVM/Oncology, US Health Outcomes, GlaxoSmithKline, 200 North 16th Street, Box 7929 (Mail Code FP 1280), Philadelphia, PA, 19102, USA

    Laura Menditto

  3. Health Economics & Outcomes, i3 Innovus, MN002-0258, 12125 Technology Drive, Eden Prairie, MN, 55344, USA

    Margaret Good

  4. Medical & Scientific Affairs, i3 Global, 10052 Mesa Ridge Court, Suite 200, San Diego, CA, 92121, USA

    April Teitelbaum

  5. Health Economics & Outcomes, i3 Innovus, MN002-0258, 12125 Technology Drive, Eden Prairie, MN, 55344, USA

    Jessica Wegner

Authors
  1. Amin Haiderali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Menditto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margaret Good
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. April Teitelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jessica Wegner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret Good.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haiderali, A., Menditto, L., Good, M. et al. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support Care Cancer 19, 843–851 (2011). https://doi.org/10.1007/s00520-010-0915-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-010-0915-9

Keywords

Search

Navigation